( . -- Modified intent-to-treat radi...)Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial,Health

. -- Modified intent-to-treat radiographic success rate -- cethromycin 88.3% (227/257) compared to Biaxin(R) 91.7% (232/253) [-8.8, +2.0] (p=0.2383). Based on the 91.7% clinical cure rate for Biaxin(R) being 90% or greater, a delta value of 10% or less on the lower bound and greater than zero on the upper bound [-8.8, +2.0] establishes non-inferiority. Under this analysis, the study met the endpoint of modified intent-to-treat radiographic success rate. Since p>0.05, there is not a statistically significant difference between cethromycin and Biaxin(R), which supports non-inferiority. -- Bacteriological cure rate -- cethromycin 89.1% (57/64) compared to Biaxin(R) 96.8% (61/63). The bacteriologically evaluable population for each arm of the trial was not powered to demonstrate statistical non-inferiority at a 95% confidence interval. -- Percent of bacteriologically evaluable patients -- approximately 28% of subjects in the per protocol population were bacteriologically evaluable. The Company believes that this percentage of bacteriologically evaluable patients is in-line with rates observed in precedent successful antibiotic drug approvals and will add to its overall bacteriologically evaluable patient database. -- Discontinuation rate -- from the modified intent-to-treat population, discontinuation rate due to adverse events was 1.6% for cethromycin and 2.8% for Biaxin(R). Total discontinuation rate (due to adverse events, clinical failure, exclusion criteria and withdrawal of consent) was 7.0% for cethromycin and 7.9% for Biaxin(R). Both cethromycin and Biaxin(R) were well tolerated with discontinuation rates similar to those observed in prior clinical trials.

Cethromycin was evaluated using a 300 mg once-daily dosing regimen compared to 250 mg twice-daily
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma